Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Psoriasis 1Plaque, Amyloid 1Lymphoma, Follicular 1Bronchiolitis Obliterans Syndrome 1Adenoma, Liver Cell 1

Interventions

Rituximab 130Cyclophosphamide 113Peripheral Blood Stem Cell Transplantation 59fludarabine phosphate 55Etoposide 47Mycophenolic Acid 44Radiotherapy 41Filgrastim 41Tacrolimus 40Whole-Body Irradiation 36Busulfan 34Melphalan 33Cyclosporine 30Cytarabine 29Methotrexate 28sargramostim 27Vincristine 27Antilymphocyte Serum 27Prednisone 26Lenalidomide 23obinutuzumab 22Doxorubicin 22Carmustine 21Bortezomib 20Methylprednisolone 19fludarabine 17Dexamethasone 17Bendamustine Hydrochloride 17ibritumomab tiuxetan 15Cord Blood Stem Cell Transplantation 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Follicular × baricitinib × Clear all
NCT01490632 2019-09-27

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Eli Lilly and Company

Phase 2 Completed
271 enrolled 32 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous, Plaque, Amyloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡